Peripheral-Blood Stem Cells Versus Bone Marrow from Unrelated Donors
10/2012
Journal Article
Authors:
Anasetti, C.;
Logan, B.;
Lee, S.;
Waller, E.;
Weisdorf, D.;
Wingard, J.;
Cutler, C.;
Westervelt, P.;
Woolfrey, A.;
Couban, S.;
, ;
Rowley, S.;
Bredeson, C.;
Carter, S.;
Horowitz, M.;
Confer, D.
Secondary:
N Engl J Med
Volume:
367
Pagination:
1487-1496
URL:
http://www.ncbi.nlm.nih.gov/pubmed/23075175
Keywords:
Adult; Bone Marrow Diseases/mortality; Bone Marrow Diseases/therapy; Bone Marrow Transplantation/adverse effects; Bone Marrow Transplantation/mortality; Cause of Death; Graft Rejection/epidemiology; Graft vs Host Disease/epidemiology; Histocompatibility
Abstract:
BACKGROUND: Randomized trials have shown that the transplantation of filgrastim-mobilized peripheral-blood stem cells from HLA-identical siblings accelerates engraftment but increases the risks of acute and chronic graft-versus-host disease (GVHD), as compared with the transplantation of bone marrow. Some studies have also shown that peripheral-blood stem cells are associated with a decreased rate of relapse and improved survival among recipients with high-risk leukemia. METHODS: We conducted a phase 3, multicenter, randomized trial of transplantation of peripheral-blood stem cells versus bone marrow from unrelated donors to compare 2-year survival probabilities with the use of an intention-to-treat analysis. Between March 2004 and September 2009, we enrolled 551 patients at 48 centers. Patients were randomly assigned in a 1:1 ratio to peripheral-blood stem-cell or bone marrow transplantation, stratified according to transplantation center and disease risk. The median follow-up of surviving patients was 36 months (interquartile range, 30 to 37). RESULTS: The overall survival rate at 2 years in the peripheral-blood group was 51% (95% confidence interval [CI], 45 to 57), as compared with 46% (95% CI, 40 to 52) in the bone marrow group (P=0.29), with an absolute difference of 5 percentage points (95% CI, -3 to 14). The overall incidence of graft failure in the peripheral-blood group was 3% (95% CI, 1 to 5), versus 9% (95% CI, 6 to 13) in the bone marrow group (P=0.002). The incidence of chronic GVHD at 2 years in the peripheral-blood group was 53% (95% CI, 45 to 61), as compared with 41% (95% CI, 34 to 48) in the bone marrow group (P=0.01). There were no significant between-group differences in the incidence of acute GVHD or relapse. CONCLUSIONS: We did not detect significant survival differences between peripheral-blood stem-cell and bone marrow transplantation from unrelated donors. Exploratory analyses of secondary end points indicated that peripheral-blood stem cells may reduce the risk of graft failure, whereas bone marrow may reduce the risk of chronic GVHD.
